Professor, Pathology, UCSF School of Medicine
Pathology
Dr. James H. McKerrow, MD
|
|
Give Review
James H. McKerrow, MD is an expert in the field of Pathology. He went to Stony Brook University School of Medicine. James McKerrow is a published doctor and has 101 publications published. The lastest was: 'Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cru...'
Publications
- Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cru...
- Polymorphisms of tumor necrosis factor alpha in Middle Eastern population with colorectal cancer.
- Recognition of the role of Natural Products as drugs to treat neglected tropical diseases by the 2015 Nobel prize in physiology or medicine.
- Protease inhibitors targeting coronavirus and filovirus entry.
- Targeting Ergosterol Biosynthesis in Leishmania donovani: Essentiality of Sterol 14alpha-demethylase.
- Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis.
- Synthesis of a sugar-based thiosemicarbazone series and structure-activity relationship versus the parasite cysteine proteases: rhodesain, cruzain and Schistosoma mans...
- Increased expression of tumor necrosis factor-α is associated with advanced colorectal cancer stages.
- Binding Mode and Potency of N-Indolyloxopyridinyl-4-aminopropanyl-Based Inhibitors Targeting Trypanosoma cruzi CYP51.
- Lead Identification to Clinical Candidate Selection: Drugs for Chagas Disease.
- 4-Aminopyridyl-Based CYP51 Inhibitors as Anti-Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo Potency.
- Determinants of disease phenotype in trypanosomatid parasites.
- Hsp90 Inhibitors as New Leads to Target Parasitic Diarrheal Diseases.
- R-Configuration of 4-Aminopyridyl-Based Inhibitors of CYP51 Confers Superior Efficacy Against Trypanosoma cruzi.
- Diversity-oriented synthesis yields a new drug lead for treatment of chagas disease.
- In vitro Efficacy of Corifungin against Acanthamoeba castellanii Trophozoites and Cysts.
- Rational Development of 4-Aminopyridyl-Based Inhibitors Targeting Trypanosoma cruzi CYP51 as Anti-Chagas Agents.
- Dissecting the Active Site of the Collagenolytic Cathepsin L3 Protease of the Invasive Stage of Fasciola hepatica.
- A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia.
- Synthetic and Natural Protease Inhibitors Provide Insights into Parasite Development, Virulence, and Pathogenesis.
- Examination of the Mode of Action of the Almiramide Family of Natural Products against the Kinetoplastid Parasite Trypanosoma brucei.
- Mapping Inhibitor Binding Modes on an Active Cysteine Protease via Nuclear Magnetic Resonance Spectroscopy.
- A Global Comparison of the Human and T. brucei Degradomes Gives Insights about Possible Parasite Drug Targets.
- Global identification of peptidase specificity by multiplex substrate profiling.
- Hit-to-Lead Development of the Chamigrane Endoperoxide Merulin A for the Treatment of African Sleeping Sickness.
- Corifungin : a new drug lead for Naegleria, identified from a high throughput screen.
- Upregulation of Retinal Dehydrogenase 2 in Alternatively Activated Macrophages during Retinoid-dependent Type-2 Immunity to Helminth Infection in Mice.
- Diverse Inhibitor Chemotypes Targeting Trypanosoma cruzi CYP51.
- A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target.
- Investigation of the Proteolytic Functions of an Expanded Cercarial Elastase Gene Family in Schistosoma mansoni.
- A blood fluke serine protease inhibitor regulates an endogenous larval elastase.
- Natural Product Libraries to Accelerate the High-Throughput Discovery of Therapeutic Leads.
- Proteomic Identification of IPSE/alpha-1 as a Major Hepatotoxin Secreted by Schistosoma mansoni Eggs.
- The Trypanosoma cruzi Protease Cruzain Mediates Immune Evasion.
- Structural basis for inhibition of the cathepsin B drug target from the human blood fluke, Schistosoma mansoni.
- IrCL1 - The haemoglobinolytic cathepsin L of the hard tick, Ixodes ricinus.
- A Screen against Leishmania Intracellular Amastigotes: Comparison to a Promastigote Screen and Identification of a Host Cell-Specific Hit.
- High Throughput Analysis of an RNAi Library Identifies Novel Kinase targets in Trypanosoma brucei.
- The oligopeptidase B of Leishmania regulates parasite enolase and immune evasion.
- Mining a cathepsin inhibitor library for new antiparasitic drug leads.
- Cruzain : the path from target validation to the clinic.
- IL-22+ CD4+ T cells are associated with therapeutic trichuris trichiura infection in an ulcerative colitis patient.
- Leishmania subtilisin is a maturase for the trypanothione reductase system and contributes to disease pathology.
- Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
- Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors.
- A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
- Additional insights on the bastadins: isolation of analogues from the sponge Ianthella cf. reticulata and exploration of the oxime configurations.
- Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy.
- Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.
- Delineation of diverse macrophage activation programs in response to intracellular parasites and cytokines.
- Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole.
- In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi.
- RNA interference in Schistosoma mansoni schistosomula: selectivity, sensitivity and operation for larger-scale screening.
- Aza-peptidyl Michael acceptor and epoxide inhibitors--potent and selective inhibitors of Schistosoma mansoni and Ixodes ricinus legumains (asparaginyl endopeptidases).
- A contiguous compartment functions as endoplasmic reticulum and endosome/lysosome in Giardia lamblia.
- Structure-guided development of selective TbcatB inhibitors.
- Vinyl sulfones as antiparasitic agents and a structural basis for drug design.
- Divergent modes of enzyme inhibition in a homologous structure-activity series.
- The aignopsanes, a new class of sesquiterpenes from selected chemotypes of the sponge Cacospongia mycofijiensis.
- Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining.
- The marine sponge Diacarnus bismarckensis as a source of peroxiterpene inhibitors of Trypanosoma brucei, the causative agent of sleeping sickness.
- Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit.
- A comparative chemogenomics strategy to predict potential drug targets in the metazoan pathogen, Schistosoma mansoni.
- SmCL3, a gastrodermal cysteine protease of the human blood fluke Schistosoma mansoni.
- Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening.
- Development of protease inhibitors for protozoan infections.
- A parasite cysteine protease is key to host protein degradation and iron acquisition.
- Metal compounds for the treatment of parasitic diseases.
- Identification of the major cysteine protease of Giardia and its role in encystation.
- Identification of a new class of nonpeptidic inhibitors of cruzain.
- Aza-peptidyl Michael acceptors. A new class of potent and selective inhibitors of asparaginyl endopeptidases (legumains) from evolutionarily diverse pathogens.
- Structural and functional relationships in the virulence-associated cathepsin L proteases of the parasitic liver fluke, Fasciola hepatica.
- Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB.
- Proteomic analysis of skin invasion by blood fluke larvae.
- RNA interference of Trypanosoma brucei cathepsin B and L affects disease progression in a mouse model.
- Host pathogen protein interactions predicted by comparative modeling.
- A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection.
- Bis-acridines as lead antiparasitic agents: structure-activity analysis of a discrete compound library in vitro.
- The structure of chagasin in complex with a cysteine protease clarifies the binding mode and evolution of an inhibitor family.
- A phagocytosis mutant of Entamoeba histolytica is less virulent due to deficient proteinase expression and release.
- Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor.
- A multienzyme network functions in intestinal protein digestion by a platyhelminth parasite.
- The common gamma chain cytokines interleukin (IL)-2 and IL-7 indirectly modulate blood fluke development via effects on CD4+ T cells.
- Drug discovery and development for neglected parasitic diseases.
- Structural basis for unique mechanisms of folding and hemoglobin binding by a malarial protease.
- Antitrypanosomal activity of 5'-deoxy-5'-(iodomethylene)adenosine and related 6-N-cyclopropyladenosine analogues.
- Proteases in parasitic diseases.
- Proteomic analysis of Schistosoma mansoni cercarial secretions.
- Designing drugs for parasitic diseases of the developing world.
- The Plasmodium falciparum cysteine protease falcipain-2 captures its substrate, hemoglobin, via a unique motif.
- A cathepsin B-like protease is required for host protein degradation in Trypanosoma brucei.
- IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent.
- A multi-enzyme cascade of hemoglobin proteolysis in the intestine of blood-feeding hookworms.
- Identification of genomic responses to collagen binding by trophozoites of Entamoeba histolytica.
- Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and T...
- Aza-peptide Michael acceptors: a new class of inhibitors specific for caspases and other clan CD cysteine proteases.
- Schistosoma mansoni: sex-specific modulation of parasite growth by host immune signals.
- A surface amebic cysteine proteinase inactivates interleukin-18.
- Cercarial elastase is encoded by a functionally conserved gene family across multiple species of schistosomes.
- Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain.
Schools
State University of New York Health Science Center At Stony Brook
SUNY Stony Brook
Doctors Specialties
- Anatomic Pathology
- Pathology
Accepted Insurances
Education
-
UCSF -
Stony Brook University School of Medicine
Hospital
-
UCSF Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Walter L. Miller, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dobri D. Kiprov, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Judith A. Doyle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Linda D. Ferrell, MD |
|
|
Dr. Wen Jing, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chuanyi M. Lu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aras N. Mattis, MD |
|
|
Dr. Scott A. Oakes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rageshree Ramachandran, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tarik Tihan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah M. Calkins, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer A. Cotter, MD
This Doctor is OpenDoctor Recommended.
|